GLP-1 Receptor Agonists and Basal Insulin Combination: An Complementary Strategy for Type 2 Diabetes Treatment Intensification
The primary goal of this integrated, multi-interventional curriculum of both live and online activities is to provide an educational initiative for primary care physicians, physician assistants (PAs) and nurse practitioners (NPs) on the advantages and disadvantages of prandial insulin, the clinical profiles of GPL-1 receptor agonists, and the benefits of combining GLP-1 receptor agonists with basal insulin.
Advisory Boards for Lilly and Sanofi US. Contracted research for DexCom, Inc.; Lexicon Pharmaceuticals, Inc.; Medtronic, Inc.; Novo Nordisk Inc.; and Sanofi US. Services provided for promotional purposes (not for CME/CE services) for Novo Nordisk Inc. (Consulting).
Ownership Interest (e.g., stocks, stock options, etc.) in Medtronic, Inc., and Sanofi US.
Speaker's Bureaus for Novo Nordisk Inc. and Takeda Pharmaceuticals U.S.A, Inc.
Advisory Board for Abbott Diabetes Care; AstraZeneca; Becton, Dickinson and Company; Bigfoot Biomedical; Biodel Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; CVS/caremark; Intarcia Therapeutics, Inc.; Janssen Pharmaceuticals, Inc.; Lexicon Pharmaceuticals, Inc.; Lilly; Medtronic, Inc.; Merck & Co., Inc.; Novo Nordisk Inc.; Omada Health; and Thermalin Diabetes, LLC. Contracted Research for Janssen Pharmaceuticals, Inc. and Medtronic Foundation.
Speaker's Bureaus for AstraZeneca; Novo Nordisk Inc.; Sanofi US. Advisory Boards for Amgen; AstraZeneca; Janssen Pharmaceuticals, Inc.; Lilly; Novo Nordisk Inc.; Sanofi US; Takeda Pharmaceuticals U.S.A., Inc. Contracted Research for Asahi Kasei Pharma America; Bayer; GI Dynamics, Inc.; and Gilead Sciences Medical Affairs. Ownership Interest (e.g. stocks, stock option, etc.) in MicroBiome Therapeutics.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, pmiCME, pmiCME Advisory Boards and Consultants, DBC Pri-Med, LLC, or Vindico Medical Education.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
pmiCME Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. pmiCME, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. pmiCME is the accredited provider for this activity.
Disclosures and Conflict of Interest
pmiCME requires all individuals in a position to influence educational content for pmiCME-certified CME activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. pmiCME assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation. pmiCME and Vindico Medical Education staff have no relevant financial relationships to disclose.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by pmiCME or DBC Pri-Med, LLC.
Questions? If you have questions about this activity, please email firstname.lastname@example.org or call (877) 477-4633.
pmiCME educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of pmiCME to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.